BioTuesdays

Tag - FHTX

Foghorn Therapeutics

HCW starts Foghorn Therapeutics at buy; PT $25

H.C. Wainwright initiated coverage of Foghorn Therapeutics (NASDAQ:FHTX) with a “buy” rating and price target of $25. The stock closed at $13.68 on Nov. 19. Foghorn is a leader in the field of chromatin biology. The...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.